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Abstract
Interleukin-6 (IL-6) is suggested to have a pathogenic role in the progression of prostate cancer
(PC), therefore representing an attractive target for new therapies. However, due to the pleiotropy
of this cytokine, targeting IL-6 results in different and unpredictable responses. In order to better
understand the mechanisms underlying the different responses to the cytokine, we focused our
attention on IL-6 receptors (IL-6Rs) that represent the ﬁrst element in the cascade of cytokine-
activated signalling pathways. IL-6 signal transduction may indeed occur through the membrane
IL-6R (classical signalling) and/or through the less studied soluble IL-6R (sIL-6R; IL-6 trans-
signalling (IL-6TS)). We provide the ﬁrst evidence how responses to IL-6 may depend on the
different content of IL-6Rs in PC. In particular, the studies of
3H-thymidine incorporation and
exploitation of different approaches (i.e. activation or inhibition of IL-6TS in sIL-6R-negative
and -positive cell lines and transfection of IL-6R siRNA) allowed us to demonstrate that IL-6TS
speciﬁcally accounts for an anti-proliferative effect of the cytokine in three PC cell lines that are
known to respond differently to IL-6. Additionally, by applying migration-, scratch- and adhesion
assays, we show that IL-6TS increases motility and migration and decreases adhesion of prostate
cells facilitating thereby processes that determine metastasis initiation and spread. Finally, by
western analyses, we uncovered an IL-6- and sIL-6R-dependent downregulation of the tumour
suppressor maspin. Collectively, these data suggest that selective targeting of IL-6TS might allow
to reﬁne the currently available experimental anti-IL-6 therapies against PC.
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Introduction
Prostatecancer(PC)isoneofthemostcommoncancers
in the western world. When the tumour is organ
conﬁned, radical prostatectomy or radiotherapy can in
most cases cure the disease. In contrast, advanced
stages of the tumour, after regression obtained with
androgen ablation therapies, eventually develop a
therapy-refractory phenotype. Median survival of men
with therapy-resistant metastatic PC is limited to only
1–2 years; at this stage of the disease, the attempts to
delay tumour progression have so far resulted in only a
few months prolongation of survival (Petrylak 2007,
Friedman et al. 2008, Lassi & Dawson 2009). A better
understanding of the mechanisms responsible for
recurrence of the tumour is the basis for any possible
therapeutical improvement.
Interleukin-6 (IL-6), a cytokine known as mediator
of immunological and inﬂammatory events, has been
shown to have a role in the development and
progression of several types of tumours (Trikha et al.
2003, Mumm & Oft 2008). In particular, clinical
observations have documented increased IL-6 levels in
plasma from patients with therapy-resistant metastatic
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disease and healthy individuals (Twillie et al. 1995,
Shariat et al. 2001, George et al. 2005). In vitro and
in vivo studies suggested a pathogenic role of this
cytokine in the progression of PC (Lin et al. 2001,
Steiner et al. 2003, 2006, Cavarretta et al. 2007,
Malinowska et al. 2009). In particular, an anti-IL-6
t h e r a p yw a ss h o w nt ob ee f f e c t i v ei ni n d u c i n g
apoptosis and regression of androgen-dependent
prostate xenografts in nude mice and the follow-
ing inhibition of the conversion to an androgen-
independent phenotype (Wallneretal.2006). Although
IL-6 represents a promising potential therapeutic
target, biological responses to IL-6 and/or anti-IL-6
treatment are pleiotropic in various PC cell lines and
xenografts conﬁrming the complexity of the IL-6
action (Naka et al. 2002).
IL-6 binds to its speciﬁc receptor, IL-6 receptor a
(IL-6R), a 80 kDa glycosylated transmembrane protein
belonging to the cytokine receptor superfamily. The
complex IL-6/IL-6R associates with the protein gp130,
a transmembrane cytokine receptor, thereby inducing
gp130 dimerisation and initiation of signal transduc-
tion mainly through the Janus kinase/signal transducers
and activators of transcription (STAT), phosphotidyli-
nositol 3-kinase/Akt and mitogen-activated protein
kinase pathways.
Neither IL-6 nor IL-6R alone iscapable ofbinding to
and activating gp130. However, a naturally occurring
soluble form of IL-6R (sIL-6R), derived either by
alternative splicing or by shedding of the membrane-
bound IL-6R (mIL-6R), is able to bind the cytokine.
The complex IL-6/sIL-6R activates gp130 also in the
absenceofthemIL-6R.Thiskindofsignaltransduction
isnamedIL-6trans-signalling(IL-6TS).TheIL-6/sIL-6R
complex may therefore potentiate the signaltransduced
by the mIL-6R or activate it in cells that do not express
the receptor (Rose-John 2003). The gp130 subunit can
also exist in a soluble form named sgp130. sgp130 has
been shown to exclusively inhibit activation of the
complex IL-6/sIL-6R without interfering with the
complex IL-6/mIL-6R (Jostock et al. 2001). Classical
and IL-6TS are thought to act in concert in mediating
the response to IL-6. However, lately, it became
evident that IL-6TS has a major relevance in the
pathogenesis and development of chronic inﬂam-
matory diseases (Scheller & Rose-John 2006, Nowell
et al. 2009), as well as in colon cancer and melanoma
(Jones et al. 2001, Kallen 2002, Becker et al. 2004,
Mitsuyama et al. 2006b, Kang et al. 2007, Wagley
et al. 2007, Nowell et al. 2009). Preclinical data
suggest the possibility to improve current therapies by
speciﬁcally inhibiting the sIL-6R (Nowell et al. 2003,
Mitsuyama et al. 2006a, Rose-John et al. 2007).
Whether classical and IL-6TS pathways may be able to
transduce speciﬁc events in PC is not known yet.
It has been reported that in a large cohort of
patients with clinically localised PC, the preoperative
serum levels of IL-6 and sIL-6R are higher in those
who will develop metastases compared to individuals
who will not experience recurrence of disease in the
following 5 years (Kattan et al. 2003, Shariat et al.
2008). Interestingly, sIL-6R showed a stronger associ-
ation with disease progression than IL-6, suggesting
a role for sIL-6R in mediating speciﬁc cytokine
effects and the spread of metastases. However, no
data proving this hypothesis are so far available in PC.
In this study, we asked whether the effects of IL-6 on
PC cell proliferation are dependent on the preferential
activation of its membrane or the soluble receptor and
whether IL-6TS may play a role in processes that
facilitate metastasis formation.
Materials and methods
Cell lines and chemicals
EP156T cells (human normal prostate epithelium,
immortalised with hTERT) (Kogan et al.2 0 0 6 )w e r e
grown in modiﬁed MCDB153 (Biological Industries,
Kibbutz Beit Haemek, Israel) supplemented with 5%
FCS (PAA Laboratories, Pasching, Austria), 50 mg/l
bovine pituitary extract (Invitrogen), penicillin/
streptomycin, 5 mg/l epidermal growth factor (Pepro-
Tech, Rocky Hill, NJ, USA) and 10 nM of the synthetic
androgen methyltrienolone R1881 (New England
Nuclear, Dreieichenhein, Germany). LNCaP, PC3,
Du145 (PC cells derived respectively from lymph
node, bone and brain metastases), 22Rv1 (Sramkoski
et al. 1999) and BPH-1 (Hayward et al. 1995)w e r e
growninRPMI1640(PAALaboratories)supplemented
with 10% FCS, penicillin/streptomycin and 2 mM
GlutaMax. LAPC4 (lymph node metastatic PC cells)
were grown in Iscove’s Modiﬁed Dulbecco’s Medium
(IMDM) supplemented with 15% foetal bovine serum
(HyClone, Szabo Scandic, Vienna, Austria) and 10 nM
R1881. LNCaP, PC3 and Du145 were obtained by the
American Type Culture Collection (Manassas, VA,
USA). BPH-1 and 22Rv1 cells were a kind gift from
Dr Jack Schalken (University Medical Center St
Radboud, Nijmegen, The Netherlands), and LAPC4
cells were kindly provided by Dr Charles Sawyers
(University of California, Los Angeles, CA, USA).
Recombinant human IL-6 and gp130/Fc Chimera
(i.e. sgp130) were purchased from R&D Systems
(Wiesbaden, Germany), and CD126 (sIL-6R) was
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Polyclonal goat maspin (C-20) antibody was purchased
fromSantaCruzBiotechnologies(SantaCruz,CA,USA)
and monoclonal mouse glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (6C5) antibody was purc-
hasedfromChemicon(Millipore,Billerica,MA,USA).
sIL-6R and sgp130 ELISA
Cells were seeded onto 6-well plates in their respective
medium containing 3% (v/v) charcoal-stripped serum
(CSS). After 72 h, sgp130 and sIL-6R levels were
assessed with the human CD130/gp130 ELISA Kit
and the CD126/IL-6R/gp80 ELISA Kit (both from
Diaclone, Stamford, CT, USA) according to the manu-
facturer’s protocol. Results were normalised to cell
number in the respective well.
RT-PCR
Experimental conditions for RT-PCR were previously
described (Malinowska et al. 2009).
Treatments
Treatments were performed in medium containing 3%
CSS. Soluble receptors were added at the concen-
trations indicated in each ﬁgure prior to exposure of
cells to the cytokine. Du145, LNCaP and EP156T cells
were treated with 5 ng/ml IL-6. Based on a previous
publication (Malinowska et al. 2009), LAPC4 were
treated with 25 ng/ml IL-6.
siRNA transfections
Cells were seeded onto 96-well or 6-well plates and
transfected on the next day with 5 or 25 nM IL-6R
siRNA On-target Plus Smart Pool IL-6Ralpha or
negative siRNA Control On-Target Plus Non-targeting
Pool (Dharmacon, Lafayette, CO, USA) by using
Lipofectamine 2000 (Invitrogen) in 3% CSS.
Proliferation assay
Proliferation assay was previously described (Puhr
et al. 2009).
Cell motility assay
Cells were cultured in full-growth medium in 24-well
cell culture inserts consisting of a transparent, 8 mm
pore diameter polyethylene terephthalate (PET) mem-
brane (BD Biosciences, Schwechat, Austria). On the
next day, medium was replaced with RPMI containing
3% CSS. Soluble receptors or vehicle and IL-6 were
added in the lower chamber. After 48 h, cells in the
upper chamber were removed with a cotton swab,
whereas the cells that traversed the membrane pores
were ﬁxed with cold methanol for 10 min. Membranes
were then mounted on microscope slides with
Vectashield Mounting Medium with 40-60-diamidino-
2-phenylindole (DAPI) (Vector Labs, Burlingame, CA,
USA). Five ﬁelds of views per membrane were
analysed by ﬂuorescence microscopy with automated
cell counting (TissueGnostics, Vienna, Austria).
Scratch assay
Cells were seeded to near conﬂuence onto 6-well plates
and treated as indicated in ﬁgure legend. A 10 ml tip
was used to make a scratch in the conﬂuent layer of
cells. After 24 h, pictures at 40-fold magniﬁcation were
taken and the remaining free area was measured using
the Magic Wand Tool of Adobe Photoshop 7.0.
Adhesion assay
Ninety-six-well plates were coated with human ﬁbro-
nectin (BD Biosciences) at a ﬁnal concentration of
2 mg/cm
2. Cells were seeded in 3% CSS RPMI in the
presence of the soluble receptors or vehicle and IL-6.
After up to 2 h of incubation, cells were washed up to
three times with PBS. As an index of cell number, a
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay (Biomedica, Vienna, Austria) was
performed on the remaining cells according to the
manufacturer’s protocol. To avoid artefacts due to
changes in cell viability, values were normalised to the
valuesobtainedfromcellsequallytreatedbutnotwashed.
Western blot analysis
Cells were processed for western blot analyses as
previously described (Cavarretta et al. 2007).
Statistical analysis
All experiments were repeated at least three times.
RT-PCR and ELISA assays were repeated twice. The
SPSS 12.0 program (Chicago, IL, USA) was used for
statistical evaluation and the Mann–Whitney U test
was used for the assessment of statistical signiﬁcance.
Results
sIL-6R and sgp130 levels in PC cell lines
We initially tested different prostate cell lines for their
ability to release the sIL-6R and the soluble gp130
receptors. We included the non-cancerous cell lines
EP156T and BPH-1, the androgen-sensitive LNCaP,
LAPC4 and 22Rv1, and the androgen-independent
PC3 and Du145 PC cell lines.
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by RT-PCR (data not shown). We found that all cell
lines secreted both soluble receptors to a different
extent (Tables 1 and 2). Amounts of sIL-6R released
by the LAPC4 cells are extremely low, sometimes in
the same range of those measured in the culture
medium (data not shown). Therefore, we considered
LAPC4 cells basically sIL-6R-negative. The addition
of IL-6 increased the levels of sgp130 in LNCaP but
not in LAPC4.
Interestingly, LNCaP-high passage (LNCaP-HP)
cells released a much higher amount of both soluble
receptors. We chose for our next experiments two
sIL-6R-positive cell lines known to respond
differently to the cytokine: LNCaP cells that are
growth-inhibited (Hobisch et al. 2001) and Du145
cells that are growth-stimulated by the cytokine
(Onuma et al. 2003).
sIL-6R mediates an anti-proliferative effect of
IL-6 in different PC cells
To unmask a possible speciﬁc role of the different
IL-6Rs on cell proliferation, we applied four app-
roaches, illustrated in Figs 1–4.
We ﬁrst analysed the effect of the cytokine on
3H-thymidine incorporation after speciﬁcally inhibi-
ting IL-6TS by pretreating the cells with increasing
doses of sgp130. In this model, IL-6 increased
proliferation of both LNCaP and Du145 cells by 20
and 40% (*P!0.05) respectively (Fig. 1A and B).
When applying this method to LNCaP-HP cells, the
effect of inhibiting IL-6TS was even more pronounced
(60%), probably due to the higher levels of sIL-6R
released by the cell line at this stage (Fig. 1C). When
the values of
3H-thymidine incorporation from sgp130/
IL-6-treated cells were expressed as a percentage
of values from vehicle/IL-6-treated cells, it became
evident that suppression of IL-6TS abrogates the
anti-proliferative effect exerted by the cytokine on
LNCaP-HP cells (Fig. 1D). The effect is sgp130
dose-dependent.
In the second approach, we investigated the effect
ofaddingincreasingdosesofsIL-6RtobothLNCaPand
Du145 cells prior to exposure to IL-6. In both cases,
we measured an increased IL-6-induced proliferation
(Fig. 2A and B). Concentrations up to 100 ng/ml
sIL-6R did not further increase proliferation (data not
shown). Thus, both inhibition of IL-6TS and increase
of sIL-6R levels caused an increase of proliferation.
In order to facilitate the interpretation of these
results, we decided to remove any contribution of the
mIL-6R, therefore unmasking the effect of sIL-6R.
In this approach, LNCaP and Du145 cells were
transfected with IL-6R siRNA or control siRNA and
exposed to sIL-6R and IL-6. Efﬁcacy of siRNA
transfection was demonstrated by RT-PCR (Fig. 3A)
and sIL-6R ELISA (Fig. 3B). sIL-6R secretion
decreased by 70 and 90% in LNCaP and Du145 cells
respectively, transfected with 25 nM IL-6R siRNA
compared to cells transfected with control siRNA.
Residual receptors were not sufﬁcient to mediate
IL-6 effects since the cytokine failed to decrease
proliferation of LNCaP cells (Fig. 3C). Transfected
cells were thus treated with increasing doses of
sIL-6R and IL-6. Again, in the presence of the
mIL-6R, i.e. in cells transfected with control siRNAs,
we could observe an increase of proliferation when
the cells were exposed to the sIL-6R. However,
Table 2 sgp130 levels in prostate cell lines under basal
conditions and after interleukin-6 (IL-6) treatment
Cell line
pg sgp130/2 ml
per 3 days per
10
6 cells
(meanGS.E.M.)
a
22Rv1 45.76G23.95
LAPC4 94.68G11.87
EP156T 143.63G8.93
PC3 391.07G95.44
LNCaP 452.74G33.42
Du145 528.28G77.15
LNCaP-HP 930.86G129.70
Cell line Treatment
Relative expression (%)
of sgp130/2 ml
per 3 days per
10
6 cells (meanGS.E.M.)
a
LNCaP 100G8.46
LNCaP 5 ng/ml IL-6 147.24G9.60
LAPC4 100G1.64
LAPC4 25 ng/ml IL-6 98.40G1.89
aSensitivity: 15 pg/ml.
Table 1 Soluble interleukin-6 receptor (sIL-6R) levels in
prostate cell lines
Cell line
pg sIL-6R/2 ml per 3 days
per 10
6 cells (meanGS.E.M.)
a
LAPC4 19.88G10.04
22Rv1 35.64G13.51
Du145 170.18G120.57
BPH-1 208.53G41.61
EP156T 246.42G8.12
LNCaP 323.63G73.42
PC3 445.17G282.58
LNCaP-HP 1363.16G183.11
aSensitivity: 5 pg/ml.
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to sIL-6R, IL-6 treatment decreased proliferation
by 30% in LNCaP cells (**P!0.01) and failed to
increase proliferation of Du145 cells (Fig. 3D and E).
Thus, it seems that sIL-6R mediates an anti-prolif-
erative effect of the cytokine.
To further conﬁrm this hypothesis, we used LAPC4
cells as a negative control for sIL-6R, as mentioned
above. These cells also express lower levels of
IL-6R mRNA compared to the other PC cell lines
considered (data not shown). Addition of IL-6 to
sIL-6R-pretreated LAPC4 cells resulted in a 25%
decrease of proliferation (**P!0.01; Fig. 4). The
results were conﬁrmed by counting the number of
cells (data not shown).
From this set of experiments, we conclude that
sIL-6R mediates an anti-proliferative effect of the
cytokine in at least three PC cell lines that are known to
respond differently to IL-6. This effect can be masked
by the presence and activation of the mIL-6R.
150
125
100
75
50
25
0
0
0
.
0
5
0
.
1
0
.
1
5
0
.
3
5
0
.
5
V
e
h
i
c
l
e
200
150
100
50
0
200
150
100
50
0
3
H
-
t
h
y
m
i
d
i
n
e
 
i
n
c
o
r
p
o
r
a
t
i
o
n
(
%
 
o
f
 
v
e
h
i
c
l
e
-
t
r
e
a
t
e
d
 
c
e
l
l
s
)
(µg/ml) sgp130
A
*
0
0
.
0
5
0
.
1
0
.
1
5
0
.
3
5
0
.
5
1
.
0
V
e
h
i
c
l
e
3
H
-
t
h
y
m
i
d
i
n
e
 
i
n
c
o
r
p
o
r
a
t
i
o
n
(
%
 
o
f
 
v
e
h
i
c
l
e
-
t
r
e
a
t
e
d
 
c
e
l
l
s
)
(µg/ml) sgp130
B
* * * * ***
0
0
.
0
5
0
.
1
0
.
1
5
0
.
2
5
0
.
3
5
0
.
5
V
e
h
i
c
l
e
3
H
-
t
h
y
m
i
d
i
n
e
 
i
n
c
o
r
p
o
r
a
t
i
o
n
(
%
 
o
f
 
v
e
h
i
c
l
e
-
t
r
e
a
t
e
d
 
c
e
l
l
s
)
(µg/ml) sgp130
C
*** ** *
150
100
50
0
0
0
.
0
5
0
.
1
0
.
1
5
0
.
2
5
0
.
3
5
0
.
5
V
e
h
i
c
l
e
w/o IL-6
5 ng/ml IL-6
3
H
-
t
h
y
m
i
d
i
n
e
 
i
n
c
o
r
p
o
r
a
t
i
o
n
(
%
 
o
f
 
I
L
-
6
-
u
n
t
r
e
a
t
e
d
 
c
e
l
l
s
)
(µg/ml) sgp130
D
*** *** *** ** ** *
Figure 1 Addition of sgp130 reveals an anti-proliferative effect
of IL-6TS in LNCaP and Du145 cells. LNCaP (A), Du145 (B)
and LNCaP-HP (C) cells were treated with increasing doses of
sgp130, as indicated, and exposed to IL-6. Proliferation was
measuredby
3H-thymidineincorporationand values,expressed
as meanGS.E.M., were referred as a percentage of vehicle-
treated samples. (D) The effect of IL-6 on LNCaP-HP cell
proliferation was assessed in the absence or presence of
increasing doses of sgp130. Values, expressed as mean
GS.E.M.,arereferredasa percentageof IL-6-untreatedsamples
*P!0.05; **P!0.01; ***P!0.001.
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Figure 2 Addition of sIL-6R and IL-6 induces proliferation
in LNCaP and Du145 cells. LNCaP (A) and Du145 (B) cells
were exposed to increasing doses of sIL-6R, as indicated, prior
to treatment with IL-6. Proliferation was measured by
3H-thymidine incorporation and values, expressed as mean
GS.E.M., were referred as a percentage of sIL-6R-untreated
samples. *P!0.05; **P!0.01; ***P!0.001.
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and migration of PC cells and decreases cell
adhesion
Based on the higher incidence of PC relapse in patients
with increased preoperative levels of sIL-6R and IL-6,
we considered a possible involvement of IL-6TS in
processes relevant to tumour metastases. To this aim,
as an index of cell motility, we tested the ability of
LNCaP, Du145 and LAPC4 cells to migrate through an
8 mm pore diameter membrane after exposure to IL-6
in the presence of sgp130, vehicle or sIL-6R. In
particular, we found that the number of migrated cells
was signiﬁcantly decreased when LNCaP and Du145
cells were exposed to sgp130 and IL-6 compared to
cells exposed to the vehicle and IL-6 (Fig. 5A and B).
Consistent with this ﬁnding, migration of LAPC4 cells
was facilitated in the presence of sIL-6R and IL-6
compared to cells exposed to IL-6 only (Fig. 5C).
Afterwards, we applied the scratch assay. Consistently,
Du145 cells migrated less after inhibition of IL-6TS
(Fig. 6). Unfortunately, LNCaP and LAPC4 cells could
not be used in this kind of assay due to their
characteristic to form clusters.
Then we investigated the involvement of the sIL-6R
on cell adhesion. To this aim, Du145 cells were seeded
on ﬁbronectin substrate in the presence of IL-6 alone or
alongwithincreasingdosesofsIL-6R.Wefoundthatthe
presence of sIL-6R caused a 25% decrease in adhesion
to the substrate (Fig. 7). However, when the cells were
pre-exposed to the IL-6TS inhibitor sgp130, there
was no signiﬁcant difference between sIL-6R-untreated
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Figure 3 Removal of the contribution of membrane IL-6R by siRNA conﬁrms the anti-proliferative effect of IL-6TS. (A) LNCaP and
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in the presence of IL-6 and sIL-6R was also observed
when LAPC4 were used (data not shown).
We concluded that sIL-6R has a role in decreasing
adhesion and increasing motility and migration of PC
cells, events that represent crucial initial steps in the
formation of metastases.
IL-6TS decreases maspin expression in
PC cell lines
In order to investigate the mechanism by which IL-6TS
may promote the spread of PC cells, we looked at the
expression of maspin, a tumour suppressor recently
shown to be involved in regulation of cell adhesion and
motility in PC (Sheng et al. 1996, Abraham et al. 2003,
Ngamkitidechakul et al. 2003). We found that the non-
cancerous epithelial prostate cells BPH-1 and EP156T
express higher basal levels of the protein compared to
the PC cell lines tested (Fig. 8). Interestingly, we found
that IL-6 decreased the expression of maspin in Du145,
LNCaP and LAPC4 cells, but not in EP156T cells
(Fig. 9A–C and F respectively). Inhibition of IL-6TS
prior to exposure to IL-6 antagonised the decrease of
maspin in LNCaP (Fig. 9E) and abrogated it in Du145
cells (Fig. 9D). Finally, a further decrease of maspin
was observed in LAPC4 cells after exposure to sIL-6R
and to IL-6. The effect is sIL-6R dose-dependent
(Fig. 10). These results contribute to understanding
the mechanisms through which the cytokine may
promote PC progression and demonstrate the involve-
ment of IL-6TS in the downregulation of the tumour
suppressor maspin.
Discussion
A pathophysiological role of IL-6 in the progression of
PC has been suggested and supported by several
in vitro and in vivo investigations leading to the idea
that anti-cytokine therapies could represent a promis-
ing attempt to slow down the evolution of this disease.
However, in vitro and preclinical studies have yielded
contrasting responses to IL-6 or anti-IL-6 antibodies.
Thus, the outcome of IL-6-targeting therapies may be
unpredictable also in PC patients, ranging from a lack
of response to beneﬁcial or detrimental effects.
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underlying the different responses to the cytokine, we
focused our attention on IL-6Rs that represent the ﬁrst
element in the cascade of signalling activated by IL-6.
In particular, we investigated which roles of IL-6 may
be speciﬁcally ascribed to IL-6TS rather than to the
classical IL-6 signalling in PC cells.
We used PC cells that express both membrane and
solublereceptorsasanaturalmIL-6RC/sIL-6RCmodel
and cells that possess virtually only the mIL-6R as a
natural mIL-6RC/sIL-6RK model. In addition, by
modifying the levels of the receptors, we created two
additional models: mIL-6RC/sIL-6RK, obtained by
speciﬁcally inhibiting IL-6TS in LNCaP and Du145
cells by sgp130; and mIL-6RK/sIL-6RC, in which the
sIL-6R has been added to the cells after knockdown of
both soluble and membrane IL-6Rs. By using these
different approaches, we were able to attribute the
capacity to mediate an anti-proliferative effect of IL-6
to the sIL-6R, regardless the cell line used. In
particular, proliferation was increased by IL-6 in both
LNCaP and Du145 cells after inhibition of IL-6TS by
sgp130. LAPC4 cells were growth inhibited by IL-6 in
the presence of sIL-6R. Based on this ﬁnding, we
expected that the addition of IL-6 and sIL-6R would
have caused a decrease of proliferation also in LNCaP
and Du145 cells; instead, we measured a signiﬁcant
increase of proliferation. Several hypotheses might
explain this apparent discrepancy; the possible exist-
ence of a still unknown complex containing both
mIL-6R and sIL-6R is intriguing. This complex would
be responsible for an increase of proliferation
whenever the sIL-6R is increased. On the other hand,
the complex IL-6/sIL-6R/gp130, already known
to activate only IL-6TS, would be responsible for a
decreased proliferation. The ﬁnal result would be
a sum of the two events. Thus, the mIL-6R would
mediate a proliferative effect of the cytokine in
competition with IL-6TS.
Further complexity was found by the fact that IL-6
increases the levels of sgp130 released from LNCaP
cells. This effect is probably mediated by the sIL-6R in
thatIL-6isnoteffectiveinLAPC4(Table2)norincells
with low levels of sIL-6R (data not shown). These data
furtherunderlinetherelevanceoftherelativecontentof
sIL-6RandmIL-6R foraspeciﬁc effect ofthe cytokine.
Consistent with our ﬁnding, a decrease of proliferation
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pleomorphic malignant ﬁbrous histiocytoma cell line
(Nakanishi et al. 2004). A fusion protein consisting of
human IL-6 and human sIL-6R was also shown to
reduce proliferation of B16 melanoma (Ozbek et al.
2001) and F10.9 cells (Wagley et al. 2007).
At this stage, the possibility of interactions between
sIL-6R and other not yet identiﬁed factors cannot be
excluded and the situation in vivo seems to be more
complex. In this regard, we cross-refer to Knupfer &
Preiss(2008)foraninterestingdiscussiononthepossible
agonistic and non-agonistic properties of sIL-6R.
Although high levels of IL-6 are considered
indicators of bad prognosis and consistently found
associated with metastases, very little data showing a
direct link between IL-6 and metastatogenesis in
different malignancies are known (Kanazawa et al.
2007, Studebaker et al. 2008); surprisingly, no reports
are so far available in the ﬁeld of PC. As previously
mentioned, an association between the levels of sIL-6R
in PC patients before prostatectomy and higher
probability to develop metastases has been found
(Kattan et al. 2003, Shariat et al. 2004, 2008). We
therefore turned our attention to the possible involve-
ment of IL-6/sIL-6R in mechanisms responsible for
cancer dissemination to secondary organs. One event
relevant to invasion and metastasis formation is the
increased motility. Interestingly, we found that
activation of IL-6TS resulted in increased motility
and migration of PC cells. In accordance with this, a
role for IL-6 in promoting migration and invasion has
been very recently reported also in breast tumour cells
(Walter et al. 2009).
Changes in adhesive properties to extracellular
matrix (ECM) components also play a critical role in
the process of tumour dissemination being an essential
prerequisite for increased acquisition of movement of
the cells. We measured an IL-6/sIL-6R-dependent
decrease of attachment of Du145 and LAPC4 cells to
one of the major components of the prostate ECM. This
is the ﬁrst evidence that IL-6TS activation may
promote PC dissemination.
In order to clarify through which mechanism IL-6
could facilitate the spread of PC cells, we considered
the tumour suppressor gene maspin, a 42 kDa serine
protease inhibitor, which has been recently proven to
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www.endocrinology-journals.org 249block tumour invasion, stimulates cell adhesion and
blocks angiogenesis in breast and PCs (Zou et al. 1994,
Sheng et al. 1996, Zhang et al. 2000, Abraham et al.
2003, Cher et al. 2003, Ngamkitidechakul et al. 2003,
Denk et al. 2007). In particular, Du145, LNCaP and
PC3 cells were shown to be inhibited in terms of
invasion and motility when treated with exogenous
recombinant maspin (Schaefer & Zhang 2003). Most
importantly, in vivo evidence that maspin inhibits
metastatogenesis was provided by Luo et al. (2007);
they demonstrated that maspin-negative PC cells from
TRAMP mice give rise to numerous liver metastases in
nude male mice, whereas forced maspin expression in
the same cells dramatically reduced their metastatic
activity. Yet, athymic nude mice inoculated with PC3-
overexpressing maspin developed signiﬁcantly fewer
and less destructive bone metastases than parental PC3
(Hall et al. 2008). We demonstrate that IL-6 decreases
the expression of maspin in Du145, LAPC4 and
LNCaP PC cells but not in the non-cancerous prostate
cells. This ﬁnding provides a mechanistic explanation
for the pathogenic role of IL-6 in PC progression.
Interestingly, inhibition of IL-6TS antagonised the
effect of the cytokine on maspin levels suggesting the
main role for the sIL-6R in mediating this effect of
IL-6. The soluble gp130 may regulate maspin
expression also in the absence of the IL-6 (data not
shown) conﬁrming the already proposed binding of
sgp130 to other ligands/soluble receptors (Montero-
Julian et al. 1997, Jones et al. 2001). However, in the
presence of the cytokine, afﬁnity of sgp130 for IL-6TS
prevails. The role of IL-6TS on maspin regulation is
further supported by experiments showing that the
levels of maspin decrease in LAPC4 cells after
exposure to sIL-6R and IL-6. Interestingly, an
increased attachment on ﬁbronectin-coated plates by
Du145 cells overexpressing maspin was also reported
(Abraham et al. 2003, Tahmatzopoulos et al. 2005).
Maspin expression is reduced in prostate tumours
and cancer cell lines compared to normal prostate
epithelial cells (Sheng et al. 1996). Consistent with
this, we also measured dramatically higher basal levels
of maspin in the non-cancerous prostate epithelial cells
compared to PC cells. Decreased expression of maspin
has been shown to correlate with breast and PC
progression (Maass et al. 2000, Pierson et al.2 0 0 2 ). In
particular, in human primary PCs, maspin expression
consistently appears to be down-regulated at the
critical transition from non-invasive, low-grade disease
to highly invasive, high-grade PC (Pierson et al. 2002).
With respect to possible signalling pathways
activated by IL-6TS, we have considered phosphoryl-
ation of STAT3, ERK1/2 and STAT1 in cells in which
IL-6TS had been previously enhanced or inhibited.
Neither signalling pathwaywas found to be speciﬁcally
activated by IL-6TS (data not shown). To the best of
our knowledge, there is so far nothing known about a
signalling pathway that can be switched on/off only by
IL-6/sIL-6R. We believe that speciﬁcity to the IL-6TS
may be given by other cytokines and/or receptors.
Future investigations in these directions are planned.
The current work showing a role of IL-6TS in
decreasing adhesion and increasing motility and
migration along with its effect on the inhibition of
maspin strongly supports the hypothesis that the
sIL-6R may have an important role in metastasis
formation. Therefore, speciﬁc targeting of IL-6TS in
PC patients might represent anelegant way toreﬁne the
currently available experimental anti-IL-6 therapies. It
would be worth in the future to determine whether the
sgp130plasmalevels,inadditiontothoseofsIL-6Rand
IL-6, are altered in PC patients with a worse prognosis.
This information may help to identify those patients
who could beneﬁt from the anti-cytokine therapy.
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